This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses and email address may be missing. Find their university profile.
Latest papers
Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.
Proceedings of the National Academy of Sciences of the United States of America · 2010
Latest funding
- $35,000
Targeting glycolysis to enhance oncolytic virotherapy
CIHR · 2025 · Supervisor
- $772,650
Targeting itaconate production to improve oncolytic virus therapy.
CIHR · 2023 · Nominated PI
1 publications.
Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.
Alain T, Lun X, Martineau Y, Sean P, Pulendran B, Petroulakis E, Zemp FJ, Lemay CG, Roy D, Bell JC, Thomas G, Kozma SC, Forsyth PA, Costa-Mattioli M, Sonenberg N
Targeting glycolysis to enhance oncolytic virotherapy
Principal investigators: Bardoul, Angelina
Keywords: B16f10 Melanoma Cancer; Ct26 Murine Colon Cancer; Glycolysis; Multiple Cancers; Oncolytic Virotherapy
Targeting itaconate production to improve oncolytic virus therapy.
Principal investigators: Roy, Dominic
Keywords: Cancer Therapy; Immunometabolism; Itaconate; Oncolytic Virus; Vesicular Stomatitis Virus
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.